» Articles » PMID: 22257841

Good Interobserver Agreement Was Attainable on Outcome Adjudication in Patients with Stable Coronary Heart Disease

Overview
Publisher Elsevier
Specialty Public Health
Date 2012 Jan 20
PMID 22257841
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: In clinical trials, agreement on outcomes is of utmost importance for valid estimation of intervention effects. As there is limited knowledge about adjudicator agreement in cardiology, we examined the level of agreement among three cardiology specialists adjudicating all possible events in a randomized controlled clinical trial of patients with stable coronary heart disease.

Study Design And Setting: All information (hospital records, death certificates, etc.) was forwarded to two randomly selected blinded adjudicators. If they disagreed, the third arbiter had to choose the more likely of the two alternatives. Files of 5,475 nonfatal and 362 fatal events were evaluated.

Results: For nonfatal outcomes, pairwise kappa values ranged from 0.75 to 0.80. The three adjudicators had 4.3%, 9.5%, and 6.1% of their nonfatal outcome classifications overruled by their arbiter. If stable angina pectoris, unstable angina pectoris, and acute myocardial infarction were treated as one, agreement increased minimally. For fatal outcomes, the pairwise kappa values ranged from 0.65 to 0.90. The three adjudicators had 12%, 9%, and 10% of their death classifications overruled.

Conclusion: Specialists in cardiology can attain a reasonably high agreement on outcomes in patients with stable coronary heart disease.

Citing Articles

Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled....

Cho I, Oh J, Kim I, Chung H, Lee J, Kim H Front Cardiovasc Med. 2022; 8:765081.

PMID: 35096995 PMC: 8790040. DOI: 10.3389/fcvm.2021.765081.


Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial.

Winkel P, Jakobsen J, Hilden J, Jensen G, Kjoller E, Sajadieh A BMJ Open. 2020; 10(8):e033720.

PMID: 32819979 PMC: 7443269. DOI: 10.1136/bmjopen-2019-033720.


Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.

Schroder J, Jakobsen J, Winkel P, Hilden J, Jensen G, Sajadieh A J Am Heart Assoc. 2020; 9(5):e014634.

PMID: 32114892 PMC: 7335588. DOI: 10.1161/JAHA.119.014634.


Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up-A CLARICOR Trial Sub-Study.

Nilsson E, Kastrup J, Sajadieh A, Jensen G, Kjoller E, Kolmos H J Clin Med. 2020; 9(1).

PMID: 31963719 PMC: 7019890. DOI: 10.3390/jcm9010265.


Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial.

Winkel P, Jakobsen J, Hilden J, Lange T, Jensen G, Kjoller E Diagn Progn Res. 2019; 1:10.

PMID: 31093541 PMC: 6460814. DOI: 10.1186/s41512-017-0009-y.